About this trial
This study aims to evaluate the relationship between the admission CALLY index and short-term adverse outcomes in STEMI patients undergoing PPCI. Specifically, it seeks to determine whether the CALLY index is associated with in-hospital and 30-day complications, including heart failure, arrhythmias, reinfarction, or death. Additionally, the study will assess the association between the CALLY index and procedural success, defined by post-intervention TIMI flow, as well as the complexity of coronary artery disease using the SYNTAX score.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of STEMI based on 4th universal definition of myocardial infarction
Undergoing Primary PCI within guideline-recommended timeframes
Provided informed consent to participate in the study
Disqualifiers
Active infection (as detected by baseline leukocytosis on admission), autoimmune or inflammatory disease affecting CRP, albumin, or lymphocyte counts
Chronic liver disease or advanced malignancy
Patients receiving immunosuppressive therapy
Refusal to participate
Trial population
The study population will consist of adult patients (≥18 years) presenting with STEMI to the emergency department and receiving PPCI as the main management
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Short-term major adverse cardiac events (MACE)
Occurrence of MACE including heart failure, arrhythmias, reinfarction, cardiogenic shock, or death.
Secondary outcomes
Procedural success of PPCI
Achievement of final TIMI 3 flow grade post-intervention without in-hospital complications.
Coronary artery disease complexity by SYNTAX score ( (Synergy Between PCI With Taxus and Cardiac Surgery score)
Assessment of the association between CALLY index at admission and coronary complexity determined by the SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score. The SYNTAX score ranges from 0 upwards, with scores categorized as 0-22 indicating low complexity and scores \>22 indicating more complex coronary artery disease. Higher scores represent increased disease complexity.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: